Seres Therapeutics (MCRB) Research & Development: 2015-2025
Historic Research & Development for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $12.6 million.
- Seres Therapeutics' Research & Development fell 23.35% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 32.87%. This contributed to the annual value of $64.6 million for FY2024, which is 45.07% down from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Research & Development is $12.6 million, which was down 2.50% from $12.9 million recorded in Q2 2025.
- Seres Therapeutics' Research & Development's 5-year high stood at $46.8 million during Q2 2023, with a 5-year trough of -$17.0 million in Q4 2022.
- For the 3-year period, Seres Therapeutics' Research & Development averaged around $21.9 million, with its median value being $16.5 million (2024).
- Its Research & Development has fluctuated over the past 5 years, first slumped by 146.39% in 2022, then skyrocketed by 235.16% in 2023.
- Over the past 5 years, Seres Therapeutics' Research & Development (Quarterly) stood at $36.8 million in 2021, then crashed by 146.39% to -$17.0 million in 2022, then skyrocketed by 235.16% to $23.0 million in 2023, then tumbled by 44.27% to $12.8 million in 2024, then fell by 23.35% to $12.6 million in 2025.
- Its Research & Development stands at $12.6 million for Q3 2025, versus $12.9 million for Q2 2025 and $11.8 million for Q1 2025.